Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 2Rectal Neoplasms 1Meningioma 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Genetic Diseases, Inborn 1

Interventions

Rituximab 13acalabrutinib 9Cyclophosphamide 9zanubrutinib 7ibrutinib 7CT-P10 7Magnetic Resonance Spectroscopy 6Cytarabine 5venetoclax 4fludarabine 4Specimen Handling 4Cyclosporine 4obinutuzumab 3fludarabine phosphate 3Whole-Body Irradiation 3Vincristine 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Methotrexate 3Lenalidomide 3Doxorubicin 3Biopsy 3Bendamustine Hydrochloride 3pirtobrutinib 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × Tablets × 30 days × Clear all
NCT04802590 2026-05-20

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

The Lymphoma Academic Research Organisation

Phase 2 Active not recruiting
210 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡